Literature DB >> 15961239

Biphasic actions of topiramate on monoamine exocytosis associated with both soluble N-ethylmaleimide-sensitive factor attachment protein receptors and Ca(2+)-induced Ca(2+)-releasing systems.

M Okada1, S Yoshida, G Zhu, S Hirose, S Kaneko.   

Abstract

To explore the pharmacological mechanisms of topiramate (TPM), we determined the effects of TPM on monoamine (dopamine and serotonin) exocytosis associated with N-ethylmaleimide-sensitive factor attachment protein receptors and Ca(2+)-induced Ca(2+)-releasing systems, including inositol-triphosphate receptor and ryanodine receptor in freely moving rat pre-frontal cortex using in vivo microdialysis. During resting stage, Ca(2+) output from endoplasmic reticulum Ca(2+) store via inositol-triphosphate receptor regulates syntaxin-associated monoamine exocytosis mechanism, whereas during neuronal hyperexcitable stage, Ca(2+) output via ryanodine receptor regulates synaptobrevin-associated monoamine exocytosis mechanism. Basal monoamine releases were increased and decreased by therapeutically relevant and supratherapeutic concentration of TPM, respectively. The therapeutic-relevant concentration of TPM increased Ca(2+)-evoked release concentration-dependently; however, its stimulatory effect was attenuated in the supratherapeutic range. The K(+)-evoked releases were reduced by TPM concentration-dependently (from therapeutic to supratherapeutic ranges). The therapeutic-relevant concentration of TPM-induced elevation of basal release was reduced by cleavage with syntaxin and inhibition of inositol-triphosphate receptor predominantly, by cleavage with SNAP-25 and synaptobrevin weakly, but not by ryanodine receptor inhibitor. The therapeutic-relevant concentration of TPM-induced elevation of Ca(2+)-evoked release was reduced by cleavage with syntaxin and inositol-triphosphate receptor inhibitor selectively. The therapeutic-relevant concentration of TPM-induced reduction of K(+)-evoked monoamine release was abolished by cleavage with synaptobrevin, but was not affected by cleavage with SNAP-25 or synaptobrevin. The stimulatory effect of ryanodine receptor agonist on K(+)-evoked monoamine release was reduced by TPM, whereas that of inositol-triphosphate receptor agonist was not affected by TPM. Therefore, these results indicate that the combination of the effects of TPM on exocytosis mechanisms associated with SNARE and Ca(2+)-induced Ca(2+)-releasing systems, enhancement of inositol-triphosphate receptor/syntaxin and inhibition of ryanodine receptor/synaptobrevin in pre-frontal cortex, may be involved in clinical actions of TPM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961239     DOI: 10.1016/j.neuroscience.2005.03.045

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  19 in total

1.  Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers.

Authors:  Mehmet Sofuoglu; James Poling; Maria Mouratidis; Thomas Kosten
Journal:  Psychopharmacology (Berl)       Date:  2006-01-24       Impact factor: 4.530

2.  Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes.

Authors:  Shunske Tanahashi; Satoshi Yamamura; Masanori Nakagawa; Eishi Motomura; Motohiro Okada
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Topiramate for smoking cessation: a randomized, placebo-controlled pilot study.

Authors:  Cheryl Oncken; Albert J Arias; Richard Feinn; Mark Litt; Jonathan Covault; Mehmet Sofuoglu; Henry R Kranzler
Journal:  Nicotine Tob Res       Date:  2013-09-21       Impact factor: 4.244

4.  Lurasidone inhibits NMDA receptor antagonist-induced functional abnormality of thalamocortical glutamatergic transmission via 5-HT7 receptor blockade.

Authors:  Motohiro Okada; Kouji Fukuyama; Yuto Ueda
Journal:  Br J Pharmacol       Date:  2019-09-15       Impact factor: 8.739

5.  ONO-2506 inhibits spike-wave discharges in a genetic animal model without affecting traditional convulsive tests via gliotransmission regulation.

Authors:  Satoshi Yamamura; Masamitsu Hoshikawa; Kato Dai; Hiromitsu Saito; Noboru Suzuki; Osamu Niwa; Motohiro Okada
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

6.  Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex.

Authors:  Satoshi Yamamura; Keiko Ohoyama; Tatsuya Hamaguchi; Kanae Kashimoto; Masanori Nakagawa; Shinichi Kanehara; Dai Suzuki; Takuya Matsumoto; Eishi Motomura; Takashi Shiroyama; Motohiro Okada
Journal:  Psychopharmacology (Berl)       Date:  2009-07-03       Impact factor: 4.530

7.  Effects of zotepine on extracellular levels of monoamine, GABA and glutamate in rat prefrontal cortex.

Authors:  S Yamamura; K Ohoyama; T Hamaguchi; M Nakagawa; D Suzuki; T Matsumoto; E Motomura; H Tanii; T Shiroyama; M Okada
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

Review 8.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

9.  Topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia.

Authors:  Yinglin Huang; Huan Ma; Yuan Wang; Miao Peng; Gang Zhu
Journal:  Neuropsychiatr Dis Treat       Date:  2017-05-24       Impact factor: 2.570

10.  Effects of topiramate on cue-induced cigarette craving and the response to a smoked cigarette in briefly abstinent smokers.

Authors:  Malcolm S Reid; Joseph Palamar; Sumithra Raghavan; Frank Flammino
Journal:  Psychopharmacology (Berl)       Date:  2007-03-08       Impact factor: 4.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.